tirzepatide receptors Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review Tirzepatide 30mg Dual GLP-1 &

Tirzepatide is approved for treating adults with type 2 diabetes but has also shown marked weight-loss efficacy in non-diabetic obese individuals, with reductions varying from 15.0% to 20.9% depending on the dose of body weight over 72 weeks in a major trial 3

Khan, S., Bano, Z., Singh, L

In March, Hengqin-based manufacturer the United Laboratories entered into a US$2-billion deal with Danish firm Novo Nordisk, which developed semaglutide, giving Novo Nordisk exclusive rights to test and sell the drug outside the Chinese mainland, Hong Kong, Macau and Taiwan

Gastrointestinal side effects were common among recipients of the once-weekly GLP-1 agonist

If symptoms become severe or persistent, medical advice should be sought